Genzyme maintained by Merrill at neutral

Genzyme Corp. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating following positive interim phase II results announced by the company and partner Schering comparing Campath and Rebif for the treatment of multiple sclerosis. Genzyme shares Friday were up $1.17, or 1.63%, at $72.83 on volume of 3,273,398 shares versus the three-month running average of 2,714,700 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.